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Building on previous multicountry surveillance studies of typhoid and others salmonelloses such as the Diseases of the Most
Impoverished program and the Typhoid Surveillance in Africa Project, several ongoing blood culture surveillance studies are
generating important data about incidence, severity, transmission, and clinical features of invasive Salmonella infections in sub-Saharan Africa and South Asia. These studies are also characterizing drug resistance patterns in their respective study sites. Each study
answers a different set of research questions and employs slightly different methodologies, and the geographies under surveillance
differ in size, population density, physician practices, access to healthcare facilities, and access to microbiologically safe water and
improved sanitation. These differences in part reflect the heterogeneity of the epidemiology of invasive salmonellosis globally, and
thus enable generation of data that are useful to policymakers in decision-making for the introduction of typhoid conjugate vaccines (TCVs). Moreover, each study is evaluating the large-scale deployment of TCVs, and may ultimately be used to assess postintroduction vaccine impact. The data generated by these studies will also be used to refine global disease burden estimates. It is
important to ensure that lessons learned from these studies not only inform vaccination policy, but also are incorporated into sustainable, low-cost, integrated vaccine-preventable disease surveillance systems.
Keywords. blood culture; enteric fever surveillance; Salmonella Typhi; typhoid fever.
Enteric fever, the collective term for typhoid and paratyphoid
fevers, describes a systemic infection caused by Salmonella
enterica serovars Typhi or Paratyphi A, B, or C. Recent
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estimates suggest that these organisms cause 14.3 million infections (95% confidence interval [CI], 12 500 000–16 300 000)
and 136 000 deaths (95% CI, 77 000–219 000) annually [1].
Invasive nontyphoidal Salmonella (iNTS) disease is caused
by other Salmonella serovars, most frequently by Salmonella
Typhimurium, Salmonella Enteritidis, or Salmonella Dublin.
Invasive nontyphoidal Salmonella disease caused an estimated
535 000 infections (95% CI, 409 000–705 000) and 77 500 deaths
(95% CI, 46 400–123 000) in 2017 [2], of which 18 400 were

attributed to human immunodeficiency virus. While improved
water treatment and sanitation infrastructure have eliminated enteric fever as a public health problem in high-income
countries, invasive Salmonella infections, which include iNTS,
remain a public health issue in many low- and lower-middleincome countries.
A major impediment to understanding the true burden of
enteric fever and iNTS disease is the lack of appropriately sensitive diagnostics and inconsistent usage of existing tests. Bone
marrow culture is considered the gold standard for diagnosis of
typhoid and paratyphoid fever, but given the invasive and challenging nature of obtaining bone marrow aspirate, it is rarely performed [3]. Often, treating physicians rely on a serological test
like the Widal test, which has limited utility in endemic settings
[4]. Blood culture–based diagnostics are recommended for use
in surveillance of typhoid fever and other invasive Salmonella
infections by the World Health Organization (WHO) [5], but
these tests are not available in most low-resource settings, which
often lack adequate resources and trained personnel required to
conduct routine blood culture tests [3]; when they are available,
blood cultures are only 40%–60% sensitive, depending in part
on the volume of blood collected and prior antibiotic usage, and
results are not available for several days, so are not useful for
decisions on empiric therapy [6].
Often, febrile patients will not present to healthcare facilities
for diagnosis and treatment. Potential deterrents to healthcare seeking include distance to and accessibility of the closest
healthcare facility, or costs associated with treatment and/or
hospitalization, combined with ease of access and affordability
of antimicrobials in the community. As a result, the true number
of invasive Salmonella infections may be underestimated.
In 2009, the WHO highlighted the need for additional data
on the burden of invasive Salmonella disease [7]. At that time,
early estimates of disease burden relied on extrapolation of data
obtained from surveillance studies conducted in limited geographical regions, which did not entirely reflect the diversity of
epidemiological settings in which typhoid is encountered [8].
A historic lack of population-based surveillance studies has
also contributed to uncertainty around disease burden, particularly in the African continent. A review of the global burden
of enteric fever conducted in 2004 showed that only 2 countries
in Africa had conducted systematic, population-based surveillance between 1954 and 2000 (South Africa and Egypt) [8].
To address the limitations of existing data sets, several surveillance studies have been established over the past decade,
funded primarily by the Bill & Melinda Gates Foundation and
the Wellcome Trust. One of the first studies funded was the
Typhoid Fever Surveillance in Africa Program (TSAP), coordinated by the International Vaccine Institute (IVI). The TSAP
study demonstrated higher overall incidence rates of typhoid
fever in sub-Saharan Africa than previously suspected across
both rural and urban sites, as well as high incidence rates of

iNTS disease across multiple sites [9]. In the years that followed, additional surveillance studies were funded to provide
more data on the burden of disease in diverse epidemiological
settings and to answer additional questions about clinical features of enteric fever, such as the prevalence of severe manifestations of disease and chronic intestinal carriage. These included
the Severe Typhoid Fever Surveillance in Africa program
(SETA, IVI); the Surveillance for Enteric Fever in Asia Project
(SEAP, Sabin Vaccine Institute); the Strategic Typhoid Alliance
Across Africa and Asia (STRATAA, University of Oxford);
and the Surveillance of Enteric Fever in India (SEFI, Christian
Medical College, Vellore). Preliminary data from these studies
have helped to inform the WHO Strategic Advisory Group of
Experts’ recommendation for typhoid conjugate vaccine (TCV)
use in the control of typhoid fever in endemic settings [10], and
additional data generated by these studies will help direct optimal use of TCVs going forward.
Each of these studies has been conducted across mutliple distinct epidemiological settings and aims to address subtly different questions relating to invasive Salmonella disease burden.
In this article, we compare the methodological similarities and
differences between these diverse and complementary studies.
We also identify early lessons learned and outstanding data
gaps, and issue recommendations for optimizing and sustaining
surveillance systems going forward.
STUDY SETTINGS AND METHODS
Severe Typhoid Fever Surveillance in Africa (SETA)

The SETA program builds on the infrastructure established as
part of the TSAP study to characterize the severity and longterm effects of typhoid fever and iNTS disease across Africa.
TSAP collected blood culture data between 2010 and 2014 and
generated typhoid incidence rates from sites in 10 sub-Saharan
African countries: Burkina Faso, Ethiopia, Ghana, GuineaBissau, Kenya, Madagascar, Senegal, South Africa, Sudan, and
Tanzania. The TSAP results showed a great deal of heterogeneity in typhoid incidence across sites, with crude rates ranging
from 0 to 284 cases per 100 000 person-years, and that there
is a high burden in both rural and urban sites [9]. SETA surveillance was continued at sites in Madagascar, Burkina Faso,
and Ghana, and surveillance was extended to include additional sites in the Democratic Republic of Congo, Ethiopia, and
Nigeria. These sites were selected based on existing evidence
of typhoid transmission and clinical microbiology capacity, as
well as to ensure geographical representativeness of key regions
within the continent.
Within each of the SETA study areas, patients were recruited
at healthcare facilities across multiple tiers. Each site included
a referral hospital, which, to be included in SETA, had to be
equipped with imaging and surgical capacity to identify and
treat intestinal perforations, as well as primary or secondary
healthcare centers, which enrolled less severe febrile subjects
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using broader enrollment criteria [11]. Each recruitment
center was assigned a geographic catchment area from which
a defined population was identified. In all countries apart from
Madagascar, the catchment area of the primary and/or secondary centers was “nested” within the catchment area of the
tertiary center. A healthcare utilization survey (HCUS) was
conducted in households randomly selected from the nested
and broader study catchment areas to estimate incidence rates
based on the proportion of the population seeking healthcare at
the respective study facilities.
Screening for study eligibility was systematically conducted at
all study facilities, including inpatient, outpatient, surgical, and
emergency wards at referral facilities. To augment case detection, Salmonella bacteremia detected in SETA laboratories from
patients who were not enrolled in the study were also included,
as well as patients with intestinal (ileal) perforation suspected
to be due to typhoid, from referral hospitals. Intestinal perforation cases were recruited into the study regardless of whether or
not the patient resided in the study catchment area. Upon enrollment, blood, stool, oropharyngeal, and urine samples were
collected. Blood was subjected to conventional microbiological
culture for detection and identification of bacterial pathogens
as well as other immunological investigations; stool was cultured to assess acute carriage status, and urine was examined
for antibiotic residues to determine patterns in antimicrobial
pretreatment.
Patients with blood culture–confirmed Salmonella Typhi,
Salmonella Paratyphi, and non-Typhi Salmonella serotype infections were recruited into the long-term follow-up component of the study. Two healthy household members and 4
healthy neighborhood controls were enrolled for each case, and
the entire cohort was followed for 1 year with contact points
at predefined intervals to collect clinical information, blood
and stool samples, and cost-of-illness and quality-of-life assessments [11].
Surveillance for Enteric Fever in Asia Project (SEAP)

SEAP is a multicountry, multisite, population-based surveillance study aimed at characterizing the burden of enteric fever
in South Asia. The project had two phases: phase 1, a retrospective clinical record review of invasive Salmonella infections, and
phase 2, a prospective surveillance study. Phase 1 showed that
Salmonella Typhi and Paratyphoid A was isolated from 0.43%
to 2% of blood cultures conducted at hospitals in Bangladesh,
Nepal, Pakistan, and India [12].
The prospective component of the study—initiated in
October 2016—was conducted at urban and periurban sites
in Bangladesh, Nepal, and Pakistan. Sites were selected to
represent diverse communities in South Asia, but choices
were constrained by the availability of laboratories capable
of performing high-quality blood cultures. In addition to patients meeting the inclusion criteria at the hospital sites, the
S104 • cid 2020:71 (Suppl 2) • Carey et al

SEAP study also recruited enteric fever cases from laboratory
networks beyond the site hospitals. Blood specimens were
collected for culture, and a subsample of participants provided urine samples to test for residual antibiotic metabolites
to understand antibiotic usage patterns. Data were collected
on clinical manifestations, markers of severity of illness, complications of illness, and antimicrobial resistance. In addition,
in collaboration with the US Centers for Disease Control and
Prevention, an economic study of enteric illness was implemented at all 3 sites [12].
SEAP used a hybrid surveillance approach, adapted from
Luby et al [13, 14], combining facility-based surveillance with
an HCUS, administered to a representative subset of households using a single-stage, cluster design; among patients with
fever lasting 3 or more days, the proportion that sought care
for the febrile episode at a study facility was used as an adjustment to the number of enteric fever cases at the facility, for the
purpose of calculating incidence and disease severity rates.
Geographic catchment areas were delineated at surveillance
sites encompassing the majority of suspected enteric fever cases
identified during phase 1. Catchment areas used administrative
boundaries so that study staff could easily determine if patients
resided in the catchment area [12]. SEAP used a hybrid surveillance approach, adapted from Luby et al [13, 14], combining
facility-based surveillance with an HCUS, which was administered to a representative subset of households using a singlestage, cluster design [13]. The proportion within the surveyed
group who reported a fever lasting 3 or more days and sought
care for the febrile episode at a study facility was then used as
an adjustment for care-seeking at the study facilities within the
catchment area.
Surveillance of Enteric Fever in India (SEFI)

There has been a lack of nationally representative enteric fever
incidence data in India, as highlighted by a 2016 meta-analysis
[15]. To fill these data gaps, the SEFI program was established
by the Christian Medical College, Vellore, and its design was
developed in collaboration with the Indian Council of Medical
Research, the Translational Health Sciences and Technology
Institute, the Indian Academy of Pediatrics, and other public
health stakeholders [16]. The SEFI team established a 3-tiered
surveillance system to estimate the age-specific incidence of enteric fever in children, examine the heterogeneity of incidence
in diverse settings across India, and generate information on
antimicrobial resistance patterns and cost of illness. Study enrollment began in October 2017.
The tier 1 surveillance for estimating the incidence of enteric
fever in children consists of active, community-based surveillance in 1 rural and 3 urban sites, which were selected to be
broadly representative of different geographic settings and population densities. At each of the 4 sites, 6000 children between
6 months and 15 years are followed each week for 2 years to

estimate the age-specific incidence rates of enteric fever in children. At least 1 contact each month is in-person and the rest are
either in-person or by telephone. Parents are also encouraged
to reach out to the study team if a child has fever in between
weekly follow-up points, and all participating families are given
thermometers and diary cards. Any fever of 3 or more consecutive days is considered a suspected case, and the child is referred
to a study facility on the fourth day of fever, where a blood culture is performed if the child has had fever in the past 12 hours.
Risk factors and other demographic data are also collected from
participating households to permit extrapolation of incidence
estimates to other similar risk settings [17].
Tier 2 is passive, hospital-based surveillance, which has been
harmonized across 6 secondary-care facilities in 6 settings (5
rural and 1 urban) with well-defined catchment populations between 100 000 and 400 000 each. All patients hospitalized at a
study facility with a fever are considered eligible. Upon consent,
a blood culture is collected irrespective of duration of fever or
temperature. Those with blood culture–confirmed enteric fever
are followed up for 28 days to capture costs and clinical complications. Biannual HCUSs are administered to 5000 randomly
selected households in 100 clusters at each site. These are used to
determine the probability of seeking healthcare at the study facility. The population denominators are estimated by projecting
annual growth rates from the 2011 census for each village in
the catchment area and validated by reviewing the population
in the sampled clusters in the HCUS. The tier 2 surveillance
system was designed to estimate the incidence of severe enteric
fever (requiring hospitalization) across all age groups.
Tier 3 surveillance is being conducted at 8 laboratories
linked to tertiary care hospitals. The aims of this component
of the surveillance system are to generate estimates of the proportion of blood cultures that are positive for Salmonella Typhi
or Paratyphi A and to characterize antimicrobial resistance
patterns. Patients with nontraumatic ileal perforations are also
enrolled in tier 2 and 3 surveillance and followed up for up to
90 days for clinical and health economic outcomes.
Strategic Typhoid Alliance Across Africa and Asia (STRATAA)

The STRATAA consortium, which includes key partners from
the University of Oxford’s Oxford Vaccine Group, the Malawi
Liverpool Wellcome Trust Clinical Research Programme,
the International Center for Diarrhoeal Disease Research,
Bangladesh (icddr,b), and the Oxford University Clinical
Research Unit (Vietnam and Nepal), has conducted a prospective multicomponent epidemiological study in 3 densely
populated urban sites in Bangladesh, Nepal, and Malawi [18].
This study combines passive febrile illness surveillance with serological surveillance. A baseline population of approximately
100 000 was established at each site by demographic census.
Field teams visited each individual house, recording GPS position and collecting epidemiological data at the household

and individual level. A census update was conducted every
6 months at the Bangladeshi site and at 12 months in Nepal,
and a final census was conducted at all 3 sites after 2 years. In
addition, 2 HCUS and water, sanitation, and hygiene surveys
were performed in each site during the surveillance period to
generate additional data on healthcare-seeking behavior and
to investigate potential disease risk factors and transmission
routes.
Passive surveillance was conducted from June 2016 in referral hospitals and primary health centers. Patients living
within the population catchment area who presented to a study
facility reporting fever of 2 days or longer or having a documented temperature of ≥ 38°C were enrolled and consented
and blood cultures were taken [18]. Age-stratified serosurveys
were performed at each study site to assess seroincidence of typhoid infection. The resulting seroincidence rates will be used
to validate and provide upper bounds on the incidence rates derived from blood culture surveillance, using host responses as
a proxy for incidence of infection. Additionally, the serosurveys
were designed to identify potential chronic carriers of S. Typhi.
After identifying individuals with a high anti-Vi antibody response, follow-up with stool collection and culture was performed to identify stool shedding.
DISCUSSION
Study Similarities

There are important methodological similarities across these
four studies. Each study includes passive, healthcare facility–
based blood culture surveillance of febrile patients to generate
crude age-stratified incidence rate estimates stratified by age.
Each study team also conducts an HCUS and applies correction factors to these crude rates to account for the proportion
of patients from within the catchment area or study population
seeking care for febrile illness at a study facility. All 4 studies
make an adjustment for eligible cases missed by the study
(either patients who met eligibility criteria but were not approached for enrollment, or who were enrolled and chose not
to consent, or both), as well as an adjustment for blood culture
sensitivity. Antimicrobial resistance patterns from sites in all 4
studies are being analyzed, and whole-genome sequencing of
selected Salmonella isolates will be available from all studies.
Cost-of-illness studies are embedded within each of these
studies, as is screening for chronic typhoid carriage.
The SEAP and SETA studies employ similar methods to calculate incidence, owing in part to efforts coordinated by the
Scientific Advisory Process for Optimal Research on Typhoid
Burden of Disease Project (SAPORT, Emory University) group
to harmonize methods; therefore, the results are more easily
compared. Both studies generate data on the incidence of severe disease and follow enteric fever patients for at least 6 weeks
to characterize long-term sequelae. SEFI tier 2 surveillance
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processes also closely resemble that of SEAP and SETA, although enrollment criteria differ across all 3 studies.
Each of the studies contributes data to advance broader enteric fever control objectives. Epidemiological data generated
from all 4 have been shared with policymakers in relevant countries in support of decision-making around TCV introduction.
The impact of TCV deployment is being evaluated or will be
evaluated at site(s) from 3 of the 4 studies, although the designs
of these studies and the delivery strategies under evaluation
differ. A TCV impact assessment is being conducted through
Kharadar General Hospital in Karachi, Pakistan (SEAP), in response to an extensively drug-resistant typhoid outbreak [19].
The University of Maryland and University of Oxford with
Typhoid Vaccine Acceleration Consortium (TyVAC) partners
are conducting 3 large-scale TCV trials at STRATAA surveillance sites: a cluster-randomized efficacy trial in Bangladesh
[20] and 2 individually randomized efficacy studies in Nepal
and Malawi [21, 22]. Interim analysis of the Nepal RCT showed
that TCV had an 82% vaccine efficacy at 1 year after vaccination in children < 15 years of age [23]. Leveraging SETA surveillance, the University of Cambridge and partners are planning 2
TCV studies through the THECA (Typhoid Conjugate Vaccine
Introductions in Africa) consortium: a cluster-randomized trial
in Ghana using a similar methodology to the TyVAC trial in
Bangladesh, as well as a mass-vaccination campaign with cohort effectiveness evaluation in the Democratic Republic of
Congo [24]. In addition, alternatives to blood culture surveillance—namely, seroepidemiology and/or environmental sampling—are being validated at sites in all 4 studies.
Study Differences

There are several differences between the methodologies of these
studies, which are important to consider when interpreting and
comparing results. While there is some overlap, the objectives are
not uniform across the 4 studies. Eligibility criteria differ, as do the
type, number, and frequency of sample collections. The approach
to estimating adjusted incidence rates differs between studies, and
for SETA and SEFI, within study tiers as well. These and other general methodological differences are summarized in Table 1.
Each study generates both crude and adjusted incidence
rates, but the approach to defining population denominators
and the choice of adjustment factors used differ. Population
denominators affect both crude and adjusted incidence rate
calculations, so this distinction is important. The STRATAA
approach to estimating the population denominator is different
from the approach used by SEAP, SETA, and SEFI tier 2, as the
demographic censuses provide precise population denominators. In SEAP, SETA, and SEFI tier 2, eligible cases come from
predefined geographic catchment areas, which is arguably less
precise but also less resource-intensive, and enables surveillance
to cover larger catchment areas. Each study employs an adjustment for blood culture sensitivity, but STRATAA samples from
S106 • cid 2020:71 (Suppl 2) • Carey et al

probability distributions informed by a recent meta-analysis of
blood culture sensitivity by volume of blood acquired per subject and reported prior antibiotic usage [25], whereas SEAP and
SETA apply the same correction factor (assuming sensitivity
of 59%) to each blood culture result [26]. For the healthcareseeking adjustment, SETA assumes the same risk of typhoid
infection for patients who seek care at a study facility and for
patients who seek care elsewhere, whereas SEAP, SEFI tier 2,
and STRATAA assume a differential typhoid risk for febrile patients who seek care at a study facility [13, 27]. SEFI tier 1 does
not include a healthcare-seeking adjustment, since it employs
active surveillance.
There are also key differences between these studies based
on the geographies under surveillance, which are illustrated in
Figure 1. The STRATAA sites are in densely populated, urban
areas, whereas SEFI, SETA, and SEAP have a mixture of urban,
periurban, and rural sites. There are observed differences in
physician practices around administration of blood culture
and clinical familiarity with typhoid fever among some South
Asian sites, and differences in the availability of antimicrobials
across all study sites. There are differences in preexisting
capacities across sites to conduct routine blood culture surveillance, and the difference in blood volumes collected and
antimicrobial usage across sites could lead to variability in the
sensitivity of results. There is also a great deal of variability in
accessibility of healthcare facilities, local water and sanitation
behaviors infrastructure, and fecal sludge management.
There is value in the diversity of these study approaches.
Some methodological differences are driven by rational, pragmatic choices made by study investigators that reflect differences between sites captured above. Each study addresses
distinct data gaps, like potential transmission routes, prevalence
of chronic carriers, and duration of immune response to natural infection, all of which will potentially inform optimal intervention strategies. Each study includes efforts to validate 1 or
more low-cost alternatives to blood culture surveillance, which
means that there is likely to be greater clarity in the near future
about which approaches, if any, are viable, feasible, and cost-effective. The diversity of settings under surveillance broadens
our understanding of the global incidence rates of typhoid fever
and other invasive Salmonella infections, which will impact prioritization and targeting of combination vaccine development
efforts. Having more broadly representative genomic data also
facilitates monitoring the evolution and spread of different antimicrobial resistance genotypes, which also should inform more
sophisticated targeting of interventions.
CONCLUSIONS

In a position paper from 2008, the WHO stated that the deployment of the then-available typhoid vaccines “should be based
on detailed knowledge of the local epidemiological situation”
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• Blood samples taken from enrolled subjects at
baseline
• For blood culture–confirmed cases of S.Typhi
and iNTS and associated controls, blood, urine,
and stool samples and oropharyngeal swabs
were taken at day 3-7, 14, 28, 90, 180, 270, and
360
• Ileal tissue or other surgical samples taken in
cases of nontraumatic ileal perforation regardless of blood culture positivity
• 1-year follow-up of blood culture–confirmed
S.Typhi and iNTS cases and controls

• Probability of seeking care at a study facility,
based on HCUS
• Proportion of eligible patients enrolled in study
• Proportion of eligible patients consenting to participate with a blood culture taken
• Sensitivity of blood culture (assumed 60%)

Incidence rate
adjustment
factors

Primary/secondary health facilities
• Objective fever of ≥ 38°C OR
• Subjective fever ≥ 3 consecutive days in the last
week
• AND reside in the nested catchment area
Referral hospitals
• Subjective fever ≥ 3 consecutive days in the last
week, OR
• Clinically suspected typhoid fever
• AND reside in the catchment area
• OR pathognomonic gastrointestinal perforations
even in the absence of laboratory confirmation
and regardless of catchment area (special cases)

Eligibility
criteria

Sample collection and
follow-up

Prospective passive, facility-based surveillance
paired with population-based HCUS
Prospective case-control cohort for long-term
follow-up

SETA

Comparison of Surveillance Methods

Design

Table 1.
SEAP

• Probability of eligible patient seeking care at a study
facility, based on HCUS
• Proportion of eligible patients who consented and
received a blood culture
• Difference in healthcare-seeking according to socioeconomic status
• Sensitivity of blood culture (assumed 59%)

• Blood samples taken from enrolled subjects at
baseline
• Urine samples taken from a sample of enrolled
subjects at baseline
• Ileal tissue samples taken in cases of nontraumatic
ileal perforation regardless of blood culture positivity
• 6-week phone call for blood culture–confirmed
cases of S. Typhi or S. Paratyphi A—patients with
complications followed up

Outpatient
• 3 days of consecutive fever in the last 7 days
• AND reside in the study catchment area
• AND physician must advise blood culture
Inpatient
• Clinical suspicion of enteric fever AND physician
must advise blood culture OR
• Confirmed diagnosis of enteric fever at any time
during hospitalization OR
• Nontraumatic ileal perforations, even in the absence of laboratory confirmation
Laboratory:
• Blood culture positive for S. Typhi or S. Paratyphi
A only

Retrospective and prospective passive, facility-based
surveillance paired with population-based HCUS

SEFI

• Probability of seeking care at a study
facility, based on HCUS
• Proportion of eligible patients who
consented and received a blood
culture
• Sensitivity of blood culture (assumed 59%)

• Blood samples taken from enrolled
subjects at baseline
• Ileal tissue samples taken in cases
of nontraumatic ileal perforation regardless of blood culture positivity
• Tier 1: Weekly follow-up, and
in-person follow-up and blood collection at 28 days for enteric fever
subcohort
• Tier 2: Phone contact at 14 and
28 days postdischarge for cost-ofillness data

Tier 1
• Subjective fever ≥ 3 consecutive
days (families given thermometers
and diary cards to record)
• AND reside in census population
area
• AND fever in the last 12 hours before presentation,
Tier 2
• All inpatients presenting with fever
OR
• Patient with nontraumatic ileal perforation
• AND residing in geographic catchment area
Tier 3
• Blood culture positive for S. Typhi or
S. Paratyphi A only

Tier 1:  Prospective population-based
cohort with active surveillance
Tier 2:  Prospective passive, hospitalbased paired with populationbased HCUS
Tier 3:  Laboratory-based surveillance

STRATAA

• Probability of seeking care at a study
facility, based on HCUS; adjusted for
the prevalence of previously identified
typhoid risk factors
• Proportion of eligible patients who
consented and had blood drawn for
culturing; adjusted for age, duration of
fever, temperature at presentation, and
clinical suspicion (Nepal and Bangladesh
only)
• Sensitivity of blood culture; adjusted
for volume and reported prior antibiotic
usage

• Blood, plasma, and stool samples taken
from enrolled subjects at baseline
• Blood, plasma, and stool samples taken
from cases and household members of
culture-confirmed cases)
• Day 8, 30, 180 follow-up

• Objective fever of ≥ 38°C OR
• Subjective fever of ≥ 2 days
• AND reside in census population area

Prospective population-based cohort
with passive surveillance paired
with population-based HCUS and
seroincidence surveys

Abbreviations: HCUS, healthcare utilization survey; iNTS, invasive nontyphoidal Salmonella; SEAP, Surveillance for Enteric Fever in Asia Project; SEFI, Surveillance of Enteric Fever in India; SETA, Severe Typhoid Fever Surveillance in Africa; STRATAA, Strategic
Typhoid Alliance Across Africa and Asia.

• Prevalence of chronic carriage,
seroincidence, antimicrobial resistance,
household transmission
• Antimicrobial resistance
• Cost of illness
• Long-term sequelae, antimicrobial resistance, cost
of illness
• Long-term sequelae, antimicrobial resistance,
natural immune response, prevalence of chronic
carriage, cost of illness, quality of life, long-term
socioeconomic study
Additional objectives

STRATAA
SEFI
SEAP
SETA

Table 1. Continued
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while simultaneously acknowledging the limitations of the existing data, particularly for the African continent [7]. In the
intervening decade, the availability of safe, immunogenic, and
efficacious TCVs [23, 28] has strengthened the need for accurate burden of disease data across diverse epidemiological
settings. In this article, we have described the design and methodology of 4 landmark surveillance studies that collectively
incorporate 44 surveillance facilities, 11 countries, and a total
population under surveillance of > 20 million people. We argue
that these studies have made large strides toward achieving the
2008 targets, and it is hoped that this article provides an important overview of the methodologies, strengths, and limitations of each individual study. Together, these data will provide
key stakeholders and country-level decision makers with more
accurate estimates of disease burden, allowing targeted, timely,
and cost-effective deployment of new preventative strategies.
The TSAP study demonstrated that there was a significant
incidence of typhoid fever and iNTS disease in Africa. SETA,
SEAP, SEFI, and STRATAA are generating data on disease
transmission, risk factors, cost of illness, and incidence of severe
disease in Africa and some parts of Asia. Furthermore, these
studies have provided baseline data in support of ongoing or
planned phase 3/4 TCV trials. Data from these studies are now
being used to enable national stakeholders to make informed
decisions on optimal TCV delivery strategies, and to direct the
development and prioritization of future Salmonella combination vaccine approaches. Methodological differences notwithstanding, each study has contributed important data to advance
global typhoid control.
Each surveillance study will provide an estimate of disease
burden for a particular setting at a particular point in time and
will reflect transmission dynamics specific to a particular setting. We acknowledge that caution should be exercised when extrapolating these figures in an attempt to provide country-level
estimates of disease burden, as the true distribution of disease
is likely to display marked intra- and intercountry and temporal
variation [29]. Furthermore, estimates of disease burden are
unlikely to be static and will likely change in response to improvements or breakdown of sanitation infrastructure and the
deployment of TCVs. Consideration should be given toward
the establishment of ongoing surveillance programs to track
changes in spatial and temporal trends in disease incidence.
Such programs should be integrated into broader, vaccinepreventable disease surveillance efforts, and should potentially
incorporate new, lower-cost alternatives to blood culture surveillance if and when these methods are validated, for maximal
sustainability.
The updated 2018 WHO position paper on typhoid vaccination recommends that “endemic countries strengthen the surveillance of typhoid fever in all age groups, and monitor the presence
of antimicrobial resistant strains of S. Typhi in endemic and epidemic disease, before and after introduction of typhoid vaccines”

Figure 1. Locations and catchment area sizes for Surveillance for Enteric Fever in Asia Project (SEAP), Severe Typhoid Fever Surveillance in Africa program (SETA),
Surveillance of Enteric Fever in India (SEFI), and Strategic Typhoid Alliance Across Africa and Asia (STRATAA) surveillance sites.

[10]. Nevertheless, the large surveillance studies described herein
are unlikely to be funded in perpetuity, and a shift in emphasis
may need to be made toward strengthening routine national
surveillance systems with a more targeted remit. It is therefore
imperative that the existing studies achieve maximal utility by addressing outstanding questions relating to age-specific incidence,
transmission, carriage, strain/serovar replacement, and incidence
post-TCV introduction. In addition, the continued validation of
alternative low-cost methods for typhoid surveillance at these sites
could yield substantial benefit to the field.
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